Complete oral bioavaliability of topotecan in combination with the Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp) inhibitor GF120918

C.M.F. Kruijtzer; J.H. Beijnen; H. Rosing; W.W. ten Bokkel Huinink; M. Schot; R.C. Jewell; E.M. Paul; J.H.M. Schellens

Complete oral bioavaliability of topotecan in combination with the Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp) inhibitor GF120918

C.M.F. Kruijtzer, J.H. Beijnen, H. Rosing, W.W. ten Bokkel Huinink, M. Schot, R.C. Jewell, E.M. Paul, J.H.M. Schellens

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2943-2950
Number of pages	7
Journal	Journal of Clinical Oncology
Volume	20
Publication status	Published - 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{cad4a7fb20694027bab40513c595b5d1,

title = "Complete oral bioavaliability of topotecan in combination with the Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp) inhibitor GF120918",

author = "C.M.F. Kruijtzer and J.H. Beijnen and H. Rosing and {ten Bokkel Huinink}, W.W. and M. Schot and R.C. Jewell and E.M. Paul and J.H.M. Schellens",

year = "2002",

language = "Undefined/Unknown",

volume = "20",

pages = "2943--2950",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Complete oral bioavaliability of topotecan in combination with the Breast Cancer Resistance Protein (BCRP) and P-glycoprotein (P-gp) inhibitor GF120918

AU - Kruijtzer, C.M.F.

AU - Beijnen, J.H.

AU - Rosing, H.

AU - ten Bokkel Huinink, W.W.

AU - Schot, M.

AU - Jewell, R.C.

AU - Paul, E.M.

AU - Schellens, J.H.M.

PY - 2002

Y1 - 2002

M3 - Article

SN - 0732-183X

VL - 20

SP - 2943

EP - 2950

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -